Meeder Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-34
Closed -$1.77K 860
2025
Q2
$1.77K Buy
+34
New +$1.94K ﹤0.01% 820
2022
Q4
Sell
-170
Closed -$7K 1294
2022
Q3
$7K Sell
170
-571
-77% -$25.2K ﹤0.01% 1449
2022
Q2
$33K Buy
741
+512
+224% +$22.1K ﹤0.01% 975
2022
Q1
$9K Buy
+229
New +$8.16K ﹤0.01% 1579
2021
Q4
Sell
-108
Closed -$4K 1663
2021
Q3
$4K Sell
108
-59
-35% -$2.47K ﹤0.01% 1997
2021
Q2
$8K Buy
167
+54
+48% +$2.39K ﹤0.01% 1775
2021
Q1
$5K Buy
113
+98
+653% +$4.47K ﹤0.01% 1855
2020
Q4
$1K Sell
15
-199
-93% -$7.15K ﹤0.01% 1658
2020
Q3
$6K Hold
214
﹤0.01% 1513
2020
Q2
$6K Buy
+214
New +$4.83K ﹤0.01% 1468
2020
Q1
Sell
-21
Closed 2396
2019
Q4
$0 Buy
+21
New +$364 ﹤0.01% 2325
2019
Q1
Sell
-983
Closed -$14K 1760
2018
Q4
$14K Sell
983
-2,625
-73% -$41.9K ﹤0.01% 1156
2018
Q3
$66K Sell
3,608
-1,413
-28% -$24.8K 0.01% 722
2018
Q2
$84.7K Buy
5,021
+4,068
+427% +$76.9K 0.01% 654
2018
Q1
$19K Buy
+953
New +$18.5K ﹤0.01% 900
2017
Q4
Sell
-184
Closed -$3K 1710
2017
Q3
$3K Sell
184
-330
-64% -$4.47K ﹤0.01% 1374
2017
Q2
$7K Sell
514
-171
-25% -$2.28K ﹤0.01% 1093
2017
Q1
$9K Sell
685
-350
-34% -$4.42K ﹤0.01% 873
2016
Q4
$10K Buy
+1,035
New +$11.3K ﹤0.01% 753
2016
Q3
Sell
-17,955
Closed -$155K 830
2016
Q2
$155K Buy
+17,955
New +$177K 0.01% 599

Other funds holding HALO

Meeder Asset Management's HALO Position: Q3 2025 in Review

Meeder Asset Management sold out of Halozyme (HALO) in Q3 2025, closing a stake of 34 shares — an estimated $1.77K sold.

Meeder Asset Management first reported a position in HALO in Q2 2016 and held it in 20 quarters. The position peaked at $155K in Q2 2016. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • Meeder Asset Management reported no remaining Halozyme position as of Q3 2025 after selling out during the quarter.
  • Meeder Asset Management sold 34 Halozyme shares in Q3 2025, an estimated $1.77K.
  • Meeder Asset Management first reported a position in Halozyme in Q2 2016 and held it in 20 quarters.
  • Meeder Asset Management's Halozyme position peaked at $155K in Q2 2016.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Meeder Asset Management's 13F filing for Q3 2025, filed 24 Oct 2025.